UBS AG announced Brenntag (ETR:BNR), bumping up its stock price target to 50.00EUR today
- Updated: September 18, 2016
Only yesterday Brenntag (ETR:BNR) traded 0.00% even at 47.94EUR. BNR’s 50-day average is 0.00EUR and its 200-day moving average is 0.00EUR. The last stock price close is up 0.00% relative to the two hundred day average, compared with the S&P 500 Index which has fallen -0.01% over the date range. Trading volume was held steady, with 0 shares of BNR changing hands on par with the typical 0 shares..
In a report released on Monday August 15 2016 UBS AG upped the target price of Brenntag (ETR:BNR) from 0EUR to 50EUR stating a possible upsideof 0.04%.
Previously on 8/14/2016, UBS AG released a statement about Brenntag(ETR:BNR) bumped the target price from 0.00EUR to 50.00EUR. At the time, this indicated a possible upside of 0.04%.
Recent Performance Graphic:
With a market capitalization of 0.0 EUR, Brenntag has a P/E of 0 with a 52 week low of 0.00EUR and a one-year high of 0.00EUR.
General Information About Brenntag (ETR:BNR)
Brenntag AG is a Germany-based company active in the field of full-line chemical distribution. It provides business-to-business distribution solutions for industrial and specialty chemicals. The Company purchases and stores large-scale quantities of industrial and specialty chemicals and repackages them into smaller quantities. In addition, the Company also offers additional services, including delivery, product mixing, blending, repackaging, micronization and fine milling, inventory management and drum return handling, as well as technical and laboratory services for specialty chemicals. The Company offers its products to a range of market industries, such as adhesives, paints, oil & gas, food, water treatment, personal care and pharmaceuticals. The Company operates through a network with more than 450 locations in Europe, North and Latin America, and in the Asia Pacific region. Its subsidiaries include, among others, and Quimicas Merono SL.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.